Posted by Michael Wonder on 09 May 2022
Health economic assessment of Abecma in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for Abecma (idecabtagene vicleucel).
The assessment concerns the treatment of adults with so-called recurrent and refractory multiple myeloma who have received at least three previous treatments, including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody, and who have shown exacerbation of the disease during the last treatment.
